D.E. Shaw & Co
PHAT icon

D.E. Shaw & Co’s Phathom Pharmaceuticals PHAT Stock Holding History

D.E. Shaw & Co’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
95,660
-36,797
-28% -$420K ﹤0.01% 3717
2026
Q1 		$1.47M Sell
132,457
-128,611
-49% -$1.62M ﹤0.01% 3153
2025
Q4 		$4.33M Buy
+261,068
New +$3.73M ﹤0.01% 2430
2024
Q4 		– Sell
-143,707
Closed -$2.6M – 4752
2024
Q3 		$2.6M Buy
+143,707
New +$2.01M ﹤0.01% 2493
2024
Q2 		– Sell
-64,138
Closed -$681K – 4771
2024
Q1 		$681K Sell
64,138
-65,251
-50% -$554K ﹤0.01% 3323
2023
Q4 		$1.18M Sell
129,389
-1,175
-0.9% -$10.1K ﹤0.01% 3028
2023
Q3 		$1.35M Buy
130,564
+16,871
+15% +$231K ﹤0.01% 2874
2023
Q2 		$1.63M Buy
+113,693
New +$1.31M ﹤0.01% 2766
2022
Q4 		– Sell
-14,477
Closed -$160K – 5055
2022
Q3 		$160K Sell
14,477
-47,781
-77% -$455K ﹤0.01% 4526
2022
Q2 		$525K Buy
+62,258
New +$640K ﹤0.01% 4061
2020
Q1 		– Sell
-7,528
Closed -$234K – 4174
2019
Q4 		$234K Buy
+7,528
New +$189K ﹤0.01% 3734

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

D.E. Shaw & Co's PHAT Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Phathom Pharmaceuticals (PHAT) stake by 28% in Q2 2026, selling an estimated $420K and leaving 95,660 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

D.E. Shaw & Co first reported a position in PHAT in Q4 2019 and has held it in 11 quarters since. The position peaked at $4.33M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • D.E. Shaw & Co held 95,660 shares of Phathom Pharmaceuticals worth $1.04M as of Q2 2026.
  • D.E. Shaw & Co sold 36,797 Phathom Pharmaceuticals shares in Q2 2026, an estimated $420K.
  • Phathom Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3717 holding.
  • D.E. Shaw & Co first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
  • D.E. Shaw & Co's Phathom Pharmaceuticals position peaked at $4.33M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.